Biogen And Sage Therapeutics Announced Zurzuvae (Zuranolone) CIV Is Now Available By Prescription For The Treatment Of Postpartum Depression For Adults In The United States
Portfolio Pulse from Benzinga Newsdesk
Biogen Inc. and Sage Therapeutics have announced that Zurzuvae (Zuranolone) CIV is now available by prescription in the United States for the treatment of postpartum depression in adults.
December 14, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's new product, Zurzuvae (Zuranolone) CIV, for postpartum depression is now available by prescription, which may lead to increased revenues.
The availability of Zurzuvae (Zuranolone) CIV in the US market is a significant development for Biogen, likely to increase its revenue as it taps into the postpartum depression treatment market. The news is directly related to Biogen and is important for investors as it represents a potential growth opportunity.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sage Therapeutics' collaboration with Biogen brings Zurzuvae (Zuranolone) CIV to the US market, which may positively impact its financial performance.
Sage Therapeutics, in collaboration with Biogen, has made Zurzuvae (Zuranolone) CIV available for prescription in the US, which is expected to contribute to the company's revenue growth. This development is directly relevant to Sage Therapeutics and holds substantial importance for investors as it could signify a new income stream.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80